Kenji Schorpp and Kamyar Hadian Pages 266 - 271 ( 6 )
Within the last few years the Helmholtz Zentrum München has established several initiatives enabling the translation of basic research results into discovery of novel small molecules that affect pathomechanisms of chronic and complex diseases. Here, one of the main operations is the Assay Development and Screening Platform (ADSP) that has state-of-the-art equipment for compound screening and provides knowledge in a variety of biochemical or cell-based phenotypic assays. In particular, ADSP has a strong focus on complex assays such as high-content screening in stem cells that are likely to provide an innovative approach complementary to biochemical assays for the discovery of novel small molecules modulating key biological processes.
Academic screening, assay development, drug discovery, high content screening, HTS, liquid handling, phenotypic screening.
Helmholtz Zentrum Munchen, Institute of Molecular Toxicology and Pharmacology, Assay Development and Screening Platform, Ingolstadter Landstr. 1, D-85764 Neuherberg, Germany.